CRISPR Therapeutics AG

32.67
-1.52 (-4.45%)
At close: Apr 03, 2025, 3:59 PM
32.63
-0.12%
After-hours: Apr 03, 2025, 07:59 PM EDT

CRISPR Therapeutics AG Statistics

Share Statistics

CRISPR Therapeutics AG has 85.77M shares outstanding. The number of shares has increased by 1.01% in one year.

Shares Outstanding 85.77M
Shares Change (YoY) 1.01%
Shares Change (QoQ) 0.49%
Owned by Institutions (%) 76.5%
Shares Floating 82.06M
Failed to Deliver (FTD) Shares 53.21K
FTD / Avg. Volume 2.48%

Short Selling Information

The latest short interest is 20.31M, so 23.8% of the outstanding shares have been sold short.

Short Interest 20.31M
Short % of Shares Out 23.8%
Short % of Float 24.87%
Short Ratio (days to cover) 11.16

Valuation Ratios

The PE ratio is -9.07 and the forward PE ratio is -8.2. CRISPR Therapeutics AG's PEG ratio is -0.07.

PE Ratio -9.07
Forward PE -8.2
PS Ratio 94.87
Forward PS 1.1
PB Ratio 1.72
P/FCF Ratio -22.95
PEG Ratio -0.07
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for CRISPR Therapeutics AG.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 22.07, with a Debt / Equity ratio of 0.12.

Current Ratio 22.07
Quick Ratio 22.07
Debt / Equity 0.12
Debt / EBITDA -0.48
Debt / FCF -1.55
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $89.06K
Profits Per Employee $-931.94K
Employee Count 393
Asset Turnover 0.02
Inventory Turnover n/a

Taxes

Income Tax 3.59M
Effective Tax Rate -0.99%

Stock Price Statistics

The stock price has increased by -47.06% in the last 52 weeks. The beta is 1.76, so CRISPR Therapeutics AG's price volatility has been higher than the market average.

Beta 1.76
52-Week Price Change -47.06%
50-Day Moving Average 42.49
200-Day Moving Average 47.31
Relative Strength Index (RSI) 31.7
Average Volume (20 Days) 2.15M

Income Statement

In the last 12 months, CRISPR Therapeutics AG had revenue of 35M and earned -366.25M in profits. Earnings per share was -4.34.

Revenue 35M
Gross Profit 37.31M
Operating Income -466.57M
Net Income -366.25M
EBITDA -466.57M
EBIT -466.57M
Earnings Per Share (EPS) -4.34
Full Income Statement

Balance Sheet

The company has 298.26M in cash and 223.69M in debt, giving a net cash position of 74.56M.

Cash & Cash Equivalents 298.26M
Total Debt 223.69M
Net Cash 74.56M
Retained Earnings -1.37B
Total Assets 2.24B
Working Capital 1.85B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -142.77M and capital expenditures -1.9M, giving a free cash flow of -144.68M.

Operating Cash Flow -142.77M
Capital Expenditures -1.9M
Free Cash Flow -144.68M
FCF Per Share -1.71
Full Cash Flow Statement

Margins

Gross margin is 106.61%, with operating and profit margins of -1333.05% and -1046.43%.

Gross Margin 106.61%
Operating Margin -1333.05%
Pretax Margin -1036.19%
Profit Margin -1046.43%
EBITDA Margin -1333.05%
EBIT Margin -1333.05%
FCF Margin -413.36%

Dividends & Yields

CRSP does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for CRSP is $82, which is 139.8% higher than the current price. The consensus rating is "Buy".

Price Target $82
Price Target Difference 139.8%
Analyst Consensus Buy
Analyst Count 19
Stock Forecasts

Scores

Altman Z-Score 4.97
Piotroski F-Score 3